Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JBM (Healthcare) Ltd. ( (HK:2161) ) has issued an announcement.
JBM (Healthcare) Limited has announced that Chief Executive Officer Patrick Wong Yat Wai will step down with effect from 30 April 2026 to pursue other career opportunities, with the board noting there is no disagreement or issues requiring shareholder attention arising from his resignation. On the same date, executive director and current chairman Derek Sum Kwong Yip, a seasoned industry figure with more than 38 years of pharmaceutical and corporate management experience and significant shareholding in the company, will assume the CEO role under a new service agreement running to March 2029, consolidating leadership and signalling continuity in strategic direction for the healthcare group and its stakeholders.
The most recent analyst rating on (HK:2161) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on JBM (Healthcare) Ltd. stock, see the HK:2161 Stock Forecast page.
More about JBM (Healthcare) Ltd.
JBM (Healthcare) Limited is a Hong Kong-listed healthcare group focused on the pharmaceutical industry, providing healthcare and pharmaceutical products with an emphasis on strategic development within the sector. The company is controlled in part through substantial shareholdings held by Lincoln’s Hill Development Limited and is led by executives with extensive experience in pharmaceutical operations and corporate management.
Average Trading Volume: 460,541
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.22B
See more data about 2161 stock on TipRanks’ Stock Analysis page.